Hall, M;
Gourley, C;
McNeish, I;
Ledermann, J;
Gore, M;
Jayson, G;
Perren, T;
... Kaye, S; + view all
(2013)
Targeted anti-vascular therapies for ovarian cancer: current evidence.
British Journal of Cancer
, 108
(2)
250 -258.
10.1038/bjc.2012.541.
![[thumbnail of bjc2012541a.pdf]](https://discovery-pp.ucl.ac.uk/style/images/fileicons/application_pdf.png) Preview |
PDF
bjc2012541a.pdf Download (412kB) |
Abstract
Ovarian cancer presents at advanced stage in around 75% of women, and despite improvements in treatments such as chemotherapy, the 5-year survival from the disease in women diagnosed between 1996 and 1999 in England and Wales was only 36%. Over 80% of patients with advanced ovarian cancer will relapse and despite a good chance of remission from further chemotherapy, they will usually die from their disease. Sequential treatment strategies are employed to maximise quality and length of life but patients eventually become resistant to cytotoxic agents. The expansion in understanding of the molecular biology that characterises cancer cells has led to the rapid development of new agents to target important pathways but the heterogeneity of ovarian cancer biology means that there is no predominant defect. This review attempts to discuss progress to date in tackling a more general target applicable to ovary cancer-angiogenesis.
| Type: | Article |
|---|---|
| Title: | Targeted anti-vascular therapies for ovarian cancer: current evidence |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1038/bjc.2012.541 |
| Publisher version: | http://dx.doi.org/10.1038/bjc.2012.541 |
| Language: | English |
| Additional information: | This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ PMCID: PMC3566823 |
| Keywords: | Angiogenesis Inhibitors, Angiopoietins, Angiostatins, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Bibenzyls, Female, Fibroblast Growth Factors, Flavonoids, Humans, Molecular Targeted Therapy, Neovascularization, Pathologic, Ovarian Neoplasms, Thrombospondins, Treatment Outcome, Vascular Endothelial Growth Factors |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > CRUK Cancer Trials Centre |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/1385542 |
Archive Staff Only
 |
View Item |
